The global market for Targeted Cancer Therapy was estimated at US$16.1 Billion in 2024 and is projected to reach US$23.2 Billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Targeted Cancer Therapy market.
Advances in genomic profiling-especially next-generation sequencing-enable clinicians to match patients with therapies that inhibit specific genetic mutations. These treatments are increasingly preferred over generalized chemotherapy due to their ability to limit systemic toxicity and increase efficacy. The segment continues to grow as pharmaceutical companies develop drugs focused on narrow cancer subtypes, often using technologies like antibody-drug conjugates, kinase inhibitors, and radiopharmaceuticals. Public health bodies and NGOs are also supporting initiatives that encourage early detection and personalized treatment planning, contributing to broader therapy access and adoption.
Segments: Therapy Type (Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Other Therapy Types); Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications); End-Use (Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use, Academic & Research Institutions End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Global Targeted Cancer Therapy Market - Key Trends & Drivers Summarized
Targeted cancer therapy, which attacks specific molecular drivers in tumors, now stands at the forefront of oncology innovation.Advances in genomic profiling-especially next-generation sequencing-enable clinicians to match patients with therapies that inhibit specific genetic mutations. These treatments are increasingly preferred over generalized chemotherapy due to their ability to limit systemic toxicity and increase efficacy. The segment continues to grow as pharmaceutical companies develop drugs focused on narrow cancer subtypes, often using technologies like antibody-drug conjugates, kinase inhibitors, and radiopharmaceuticals. Public health bodies and NGOs are also supporting initiatives that encourage early detection and personalized treatment planning, contributing to broader therapy access and adoption.
What Technological Innovations Are Boosting Adoption?
Antibody-drug conjugates are redefining precision oncology by delivering cytotoxic agents directly to tumor cells, reducing off-target effects. Radiopharmaceuticals are also transforming treatment paradigms, particularly in solid tumors and metastatic conditions. Artificial intelligence is enabling more effective biomarker discovery, patient stratification, and trial design. In tandem, new diagnostic techniques such as liquid biopsies offer non-invasive, real-time monitoring of cancer progression. These are complemented by regulatory frameworks that support accelerated approvals and access programs, although challenges related to cost and equity remain prevalent in many regions.The Growth in the Targeted Cancer Therapy Market Is Driven by Several Factors
The growth in the targeted cancer therapy market is driven by several factors related to genomics, therapeutic advancement, and system-wide adoption. The increasing global cancer burden is expanding demand for more personalized and effective solutions. Improved genomic screening capabilities have expanded the population eligible for precision therapies. Emerging modalities like radiopharmaceuticals and biologics are expanding treatment scope. Artificial intelligence and machine learning tools are improving treatment matching and drug development. Additionally, strategic collaborations and innovative payment models are helping overcome access barriers and drive adoption across diverse healthcare systems.Scope Of Study:
The report analyzes the Targeted Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:Segments: Therapy Type (Hormone Therapy, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Other Therapy Types); Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Other Cancer Disease Indications); End-Use (Hospitals & Clinics End-Use, Cancer & Radiation Therapy Centers End-Use, Academic & Research Institutions End-Use)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Hormone Therapy segment, which is expected to reach US$7.0 Billion by 2030 with a CAGR of a 8.0%. The Monoclonal Antibodies segment is also set to grow at 7.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $4.4 Billion in 2024, and China, forecasted to grow at an impressive 10.3% CAGR to reach $4.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Targeted Cancer Therapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Targeted Cancer Therapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Targeted Cancer Therapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Inc., Addex Therapeutics Ltd., Amgen Inc., AstraZeneca plc, Bayer AG and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 42 companies featured in this Targeted Cancer Therapy market report include:
- AbbVie Inc.
- Addex Therapeutics Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- BeOne Medicines (BeiGene)
- BioNTech SE
- Bristol-Myers Squibb Company
- Contera Pharma
- Daiichi Sankyo Co., Ltd.
- GSK plc.
- ImmunoGen, Inc.
- Merck & Co., Inc.
- Mirati Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Roche (F. Hoffmann-La Roche Ltd.)
- Sanofi
- Seagen, Inc.
- Takeda Pharmaceutical Co. Ltd.
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Addex Therapeutics Ltd.
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- BeOne Medicines (BeiGene)
- BioNTech SE
- Bristol-Myers Squibb Company
- Contera Pharma
- Daiichi Sankyo Co., Ltd.
- GSK plc.
- ImmunoGen, Inc.
- Merck & Co., Inc.
- Mirati Therapeutics, Inc.
- Novartis AG
- Pfizer Inc.
- Roche (F. Hoffmann-La Roche Ltd.)
- Sanofi
- Seagen, Inc.
- Takeda Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 396 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value in 2024 | 16.1 Billion |
| Forecasted Market Value by 2030 | 23.2 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
